Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics.

MLA

Panda, Devasis, et al. “Utility of CD36 as a Novel Addition to the Immunophenotypic Signature of RAM-Phenotype Acute Myeloid Leukemia and Study of Its Clinicopathological Characteristics.” Cytometry. Part B, Clinical Cytometry, vol. 100, no. 2, Mar. 2021, pp. 206–17. EBSCOhost, https://doi.org/10.1002/cyto.b.21943.

APA

Panda, D., Chatterjee, G., Sardana, R., Khanka, T., Ghogale, S., Deshpande, N., Badrinath, Y., Shetty, D., Narula, G., Banavali, S., Patkar, N. V., Gujral, S., Subramanian, P. G., & Tembhare, P. R. (2021). Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics. Cytometry. Part B, Clinical Cytometry, 100(2), 206–217. https://doi.org/10.1002/cyto.b.21943

Chicago

Panda, Devasis, Gaurav Chatterjee, Rohan Sardana, Twinkle Khanka, Sitaram Ghogale, Nilesh Deshpande, Yajamanam Badrinath, et al. 2021. “Utility of CD36 as a Novel Addition to the Immunophenotypic Signature of RAM-Phenotype Acute Myeloid Leukemia and Study of Its Clinicopathological Characteristics.” Cytometry. Part B, Clinical Cytometry 100 (2): 206–17. doi:10.1002/cyto.b.21943.